NS-2028

Names

[ CAS No. ]:
204326-43-2

[ Name ]:
NS-2028

[Synonym ]:
4H-8-BROMO-1,2,4-OXADIAZOLO(3,4-D)BENZO(B)(1,4)OXAZIN-1-ONE
8-BROMO-4H-2,5-DIOXA-3,9B-DIAZA CYCLOPENTA[A]NAPHTHALEN-1-ONE
Kartogenin
4H-8-Bromo-1,2,4-oxadiazolo[3,4-d]benz[b][1,4]oxazin-1-one
NS-2028
1H,4H-[1,2,4]Oxadiazolo[3,4-c][1,4]benzoxazin-1-one, 8-bromo-
8-Bromo-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one

Biological Activity

[Description]:

NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity[1]. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM[1]. NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM[1]. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM)[1]. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability[2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> GPCR/G Protein >> Guanylate Cyclase

[Target]

IC50: 30 nM (soluble Guanylyl Cyclase sGC)[1]

[In Vitro]

NS-2028 (10 μM; 24 hours) inhibits 25% cell number in comparation with those grown in the presence of vehicle[2]. NS-2028 (10 μM; 30 mins) attenuates VEGF-induced EC migration by inhibiting p38 MAPK activation[2]. Cell Proliferation Assay[2] Cell Line: HUVEC cells Concentration: 10 μM Incubation Time: 24 hours Result: Decreased cell numbers in culture. Western Blot Analysis[2] Cell Line: HUVEC cells Concentration: 10 μM Incubation Time: 30 mins Result: Attenuated VEGF-enhanced p38 phosphorylation.

[In Vivo]

NS-2028 (Deliver orally; 1 g/L; 8 days) exhibits a significant reduction of new vessel formation in the avascular rabbit cornea in response to VEGF pellet implants[2]. Animal Model: Rabbit[2] Dosage: 1 g/L Administration: Deliver orally; 1g/L; 8 days Result: Inhibits VEGF-induced angiogenesis in vivo.

[References]

[1]. Olesen SP, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309.

[2]. Morbidelli L, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32.

Chemical & Physical Properties

[ Density]:
2.1±0.1 g/cm3

[ Boiling Point ]:
353.8±52.0 °C at 760 mmHg

[ Melting Point ]:
161-162ºC

[ Molecular Formula ]:
C₉H₅BrN₂O₃

[ Molecular Weight ]:
269.052

[ Flash Point ]:
167.8±30.7 °C

[ Exact Mass ]:
267.948334

[ PSA ]:
57.26000

[ LogP ]:
0.27

[ Vapour Pressure ]:
0.0±0.8 mmHg at 25°C

[ Index of Refraction ]:
1.778

MSDS

Click to get detail MSDS

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

Articles

Contribution of nitric oxide-dependent guanylate cyclase and reactive oxygen species signaling pathways to desensitization of μ-opioid receptors in the rat locus coeruleus.

Neuropharmacology 99 , 422-31, (2015)

Nitric oxide (NO) is involved in desensitization of μ-opioid receptors (MOR). We used extracellular recordings in vitro to unmask the NO-dependent pathways involved in MOR desensitization in the rat l...

Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.

Br. J. Pharmacol. 123 , 299-309, (1998)

1 The haeme-containing soluble guanylyl cyclase (alpha1beta1-heterodimer) is a major intracellular receptor and effector for nitric oxide (NO) and carbon monoxide (CO) and mediates many of their biolo...